KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

West Pharmaceutical Services (WST) Income from Continuing Operations (2016 - 2026)

West Pharmaceutical Services has reported Income from Continuing Operations over the past 18 years, most recently at 135400000.0 for Q1 2026.

  • Quarterly Income from Continuing Operations rose 56.71% to 135400000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 528300000.0 through Mar 2026, up 16.52% year-over-year, with the annual reading at 479300000.0 for FY2025, 0.27% changed from the prior year.
  • Income from Continuing Operations was 135400000.0 for Q1 2026 at West Pharmaceutical Services, up from 128200000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 183000000.0 in Q2 2022 and troughed at 86400000.0 in Q1 2025.
  • The 5-year median for Income from Continuing Operations is 132100000.0 (2024), against an average of 131388235.29.
  • Biggest five-year swings in Income from Continuing Operations: crashed 32.43% in 2022 and later surged 56.71% in 2026.
  • Tracing WST's Income from Continuing Operations over 5 years: stood at 99800000.0 in 2022, then skyrocketed by 33.97% to 133700000.0 in 2023, then fell by 4.19% to 128100000.0 in 2024, then grew by 0.08% to 128200000.0 in 2025, then increased by 5.62% to 135400000.0 in 2026.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 135400000.0, 128200000.0, and 137900000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.